Good News on Cancer?

GlaxoSmithKline may be onto something very good:

GlaxoSmithKline Plc’s drug Tykerb, in an unexpected finding, cut the number of breast cancer stem cells by half in 30 patients, and two-thirds were cancer free after follow-up treatment with other therapies.

The finding, reported today at the San Antonio Breast Cancer Symposium in Texas, supports the newest theory in cancer, that a tiny number of stem cells lurking within tumors are the driving force that fuels their growth. Researchers from Baylor College of Medicine in Houston said the finding may be a first step toward changing the way cancer is treated.

This seems like great news for breast cancer victims and maybe others with cancer.